Product Name:4-{6-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl}morpholine

IUPAC Name:4-{6-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl}morpholine

CAS:2448173-19-9
Molecular Formula:C10H11IN4O
Purity:95%+
Catalog Number:CM1045040
Molecular Weight:330.13

Packing Unit Available Stock Price($) Quantity

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:2448173-19-9
Molecular Formula:C10H11IN4O
Melting Point:-
Smiles Code:IC1=CC2=C(N=CN=C2N1)N1CCOCC1
Density:
Catalog Number:CM1045040
Molecular Weight:330.13
Boiling Point:
MDL No:
Storage:

Category Infos

Pyrrolopyrimidines
Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.

Column Infos

BMF-219
Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.

Related Products